European Archives - Page 39 of 1145 - European Medical Journal

Emerging Resistance to Newest Antibiotic Ceftazidime/Avibactam

Ceftazidime/avibactam, a key antimicrobial against multidrug-resistant Gram-negative pathogens, has seen increasing use across England since its 2017 launch.

Bacteria Found to Drive Prostate Cancer Progression

Commensal bacteria from the gut, urinary tract, and prostate tissue may play an unexpected role in the progression of prostate cancer.

Deep Learning Boosts CT Diagnosis of Heart Ischaemia

AI model improves heart disease risk prediction by analysing CT scans and identifying ischaemic heart volume automatically.

New Risk Model Predicts Hyperkalaemia in Chronic Kidney Disease and Type 2 Diabetes

New risk model predicts hyperkalaemia in CKD and diabetes, enabling tailored care and safer treatment decisions for patients.

US unveils new universal vaccine platform

Generation Gold Standard is a universal vaccine platform targeting influenza, coronaviruses and future pandemics.

Switch to Tirzepatide May Give Superior Glycaemic and Weight Benefits

Switching to tirzepatide yields greater HbA1c and weight reductions than escalating dulaglutide in Type 2 diabetes.

Rethinking High-Dose Aspirin in Kawasaki Disease Treatment

A recent randomised clinical trial sought to determine whether high-dose aspirin remains necessary during acute-stage KD treatment.

Population Size Affects Liver Transplant Waiting List Outcomes

A nationwide retrospective cohort study was conducted to assess the impact of population size on waiting list outcomes for patients with acute liver failure.

New AI System Detects Spinal Fractures with 64% Accuracy: WCO 2025

A new study shows that artificial intelligence could be a valuable ally in identifying osteoporotic vertebral compression fractures (VCFs), a common yet underdiagnosed complication of aging.

Handshake on green background

Novartis acquires Regulus Therapeutics and potential first-in-class therapeutic

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor to its renal pipeline.